Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer

Sponsor
University College, London
Study ID
NCT03430700
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    Intravenous infusion

Study Details

The overall aim of the study is to demonstrate a clinically meaningful extension of progression free survival using maintenance pembrolizumab. The aim of the translational research is to study the immune microenvironment before and during pembrolizumab therapy.

Key Dates

Start date
May 16, 2019
Status verified
May 2026
Primary completion
Dec 3, 2025
Completion
Dec 3, 2025

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Maintenance treatment with trial drug pembrolizumab; 200mg IV every 21 days until progression, unacceptable toxicity, patient or clinician decision.

Primary Outcome Measure

Progression-Free Survival Rate at 6 Months From Start of Study Treatment (Maintenance Pembrolizumab) [ Time Frame: 6 months from start of study treatment (maintenance pembrolizumab) ]

Related coverage on Hipa.ai

Related Studies